Triptorelin
Triptorelin (Trelstar) is a one-, three- or six-monthly injection that switches off testosterone production for men with advanced prostate cancer.
Overview
Triptorelin pamoate was approved by the FDA in June 2000 (3.75 mg monthly), with 11.25 mg three-monthly (2001) and 22.5 mg six-monthly (2010) depots following, for palliative treatment of advanced prostate cancer; the pivotal randomised trial of 277 men showed castrate testosterone suppression comparable to leuprolide. As Decapeptyl it has been used in Europe since the 1980s for prostate cancer, endometriosis and, in premenopausal breast cancer, for ovarian function suppression in the SOFT and TEXT trials that established the combination with exemestane. Hot flushes, loss of bone density, metabolic effects and initial flare (covered with an antiandrogen) are shared with the class.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2000 | Palliative treatment of advanced prostate cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Triptorelin" OR ABSTRACT:"Triptorelin" OR TITLE:"Trelstar" OR ABSTRACT:"Trelstar" OR TITLE:"Decapeptyl" OR ABSTRACT:"Decapeptyl" OR TITLE:"Triptodur paediatric" OR ABSTRACT:"Triptodur paediatric") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Triptorelin, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductToremifene
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductIxabepilone
Shares HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductThiotepa
Shares HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductFlutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tag nci-list.
- ProductNilutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tag nci-list.
- ProductRaloxifene
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductDenosumab
Shares Prostate cancer, HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductMitoxantrone
Shares Prostate cancer and the tag nci-list.